EUVIMEDEUVIMED entdecken
Crossref

In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease

Jiawei Zhao iD, Yingjie Wang, Yiquan Zhang, Xinyu Guo, Han Bao, Yong Tao iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202402523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Jiawei Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, P. R. China. Hauptthemen laut MEDLINE: Cerium, Extracellular Vesicles, Mesenchymal Stem Cells, Uveitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority's Ascent Program, Capital Health Development Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Posterior uveitis is a leading cause of vision impairment and blindness globally due to its detrimental effects on the choroid and retina. The condition is worsened by oxidative stress, which heightens inflammation and perpetuates a cycle of damage that current treatments only temporarily relieve. To address this, a novel treatment involving the in situ crystallization of ultrasmall cerium oxide nanoparticles (≈3 nm) on mesenchymal stem cell (MSC) extracellular vesicles (EVs) for the management of primed mycobacterial uveitis (PMU) is developed. This nanohybrid leverages the individual and synergistic effects of its components for a comprehensive therapeutic approach. The cerium oxide nanoparticles act as a nanozyme to reduce inflammation and scavenge excessive reactive oxygen species (ROS), while the MSC EVs, with their biocompatibility, modulate inflammatory cell infiltration and alleviate tissue damage. This synergistic system offers a promising new treatment strategy for ocular diseases characterized by oxidative stress and inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeriumExtracellular VesiclesMesenchymal Stem CellsUveitisAnimalsMiceHumansNanoparticlesReactive Oxygen SpeciesOxidative StressInflammationCrystallization

Stichwörter der Autor:innen

antioxidative treatmentceria‐vesicleintraocular inflammationnanozymeuveitis

Substanzen

Ceriumceric oxideReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, P. R. China.

ORCID-Profile: Jiawei Zhao, Yong Tao

Förderung

  • National Natural Science Foundation of China
  • Beijing Hospitals Authority's Ascent Program
  • Capital Health Development Scientific Research Project
  • Beijing Nova Program
  • Chinese Institutes for Medical Research
  • Excellent Young Talent Innovation Project

Zitieren

APA

Zhao, J., Wang, Y., Zhang, Y., Guo, X., Bao, H., & Tao, Y. (2025). In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402523

Vancouver

Zhao J, Wang Y, Zhang Y, Guo X, Bao H, Tao Y. In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402523

BibTeX
@article{Zhao2025,
  author = {Zhao, Jiawei and Wang, Yingjie and Zhang, Yiquan and Guo, Xinyu and Bao, Han and Tao, Yong},
  title = {In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202402523}
}
Kostenlos starten →